Literature DB >> 10664674

Imaging for recurrent prostate cancer.

D M Nudell1, A E Wefer, H Hricak, P R Carroll.   

Abstract

Multiple imaging modalities are available to evaluate recurrent prostate cancer following primary treatment with RP, RT, or cryo-surgery. These tests must be used in close conjunction with clinical parameters, such as the characteristics of the tumor itself (grade, stage) as well as specific PSA characteristics that can help predict the sites of probable recurrence. Figure 19 represents an algorithm of how patients can be monitored for recurrence according to their mode of primary treatment. As more treatments become available for recurrent prostate cancer, it will be necessary to monitor disease response with many of the imaging modalities discussed in this article.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10664674     DOI: 10.1016/s0033-8389(05)70157-3

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  10 in total

Review 1.  Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.

Authors:  Tobias Franiel; Bernd Hamm; Hedvig Hricak
Journal:  Eur Radiol       Date:  2010-12-24       Impact factor: 5.315

Review 2.  Imaging angiogenesis of genitourinary tumors.

Authors:  Ying-Kiat Zee; James P B O'Connor; Geoff J M Parker; Alan Jackson; Andrew R Clamp; M Ben Taylor; Noel W Clarke; Gordon C Jayson
Journal:  Nat Rev Urol       Date:  2010-01-19       Impact factor: 14.432

3.  Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy.

Authors:  Zohar A Dotan; Fernando J Bianco; Farhang Rabbani; James A Eastham; Paul Fearn; Howard I Scher; Kevin W Kelly; Hui-Ni Chen; Heiko Schöder; Hedvig Hricak; Peter T Scardino; Michael W Kattan
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

Review 4.  The next generation of positron emission tomography radiopharmaceuticals in oncology.

Authors:  Samuel L Rice; Celeste A Roney; Pierre Daumar; Jason S Lewis
Journal:  Semin Nucl Med       Date:  2011-07       Impact factor: 4.446

5.  Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience.

Authors:  Darko Pucar; Amita Shukla-Dave; Hedvig Hricak; Chaya S Moskowitz; Kentaro Kuroiwa; Semra Olgac; Lanie E Ebora; Peter T Scardino; Jason A Koutcher; Kristen L Zakian
Journal:  Radiology       Date:  2005-06-21       Impact factor: 11.105

6.  Detection and staging of radio-recurrent prostate cancer using multiparametric MRI.

Authors:  Jie-Ying Kowa; Neil Soneji; S Aslam Sohaib; Erik Mayer; Stephen Hazell; Nicholas Butterfield; Joshua Shur; Derfel Ap Dafydd
Journal:  Br J Radiol       Date:  2021-02-15       Impact factor: 3.039

7.  Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy.

Authors:  Satyajit Kosuri; Naveed H Akhtar; Michael Smith; Joseph R Osborne; Scott T Tagawa
Journal:  Adv Urol       Date:  2012-05-28

8.  [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

Authors:  Marino Cimitan; Roberto Bortolus; Sandro Morassut; Vincenzo Canzonieri; Antonio Garbeglio; Tanja Baresic; Eugenio Borsatti; Annalisa Drigo; Mauro G Trovò
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-25       Impact factor: 10.057

9.  Management of biochemical recurrence after primary localized therapy for prostate cancer.

Authors:  Oussama M Darwish; Ganesh V Raj
Journal:  Front Oncol       Date:  2012-05-23       Impact factor: 6.244

Review 10.  Multiparametric MRI for recurrent prostate cancer post radical prostatectomy and postradiation therapy.

Authors:  Flavio Barchetti; Valeria Panebianco
Journal:  Biomed Res Int       Date:  2014-05-25       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.